| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Carbonell, Cristina |
| dc.contributor.author | Marcos, Miguel |
| dc.contributor.author | Guillen Del Castillo, Alfredo |
| dc.contributor.author | Rubio-Rivas, Manuel |
| dc.contributor.author | Argibay, Ana |
| dc.contributor.author | Marín Ballvé, Adela |
| dc.contributor.author | Fonollosa Pla, Vicenç |
| dc.contributor.author | Simeón Aznar, Carmen Pilar |
| dc.date.accessioned | 2022-10-24T08:53:28Z |
| dc.date.available | 2022-10-24T08:53:28Z |
| dc.date.issued | 2022-10 |
| dc.identifier.citation | Carbonell C, Marcos M, Guillén-del-Castillo A, Rubio-Rivas M, Argibay A, Marín-Ballvé A, et al. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE). Autoimmun Rev. 2022 Oct;21(10):103167. |
| dc.identifier.issn | 1568-9972 |
| dc.identifier.uri | https://hdl.handle.net/11351/8332 |
| dc.description | Anticentromere antibody; Cancer; Systemic sclerosis |
| dc.description.abstract | Aim
Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non–SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with SSc using standardized incidence ratios (SIRs) and identified independent cancer risk factors in this population.
Material and methods
Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confidence intervals (CIs) relative to the general Spanish population were calculated.
Results
Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36–1.60; P < 0.001), and of lung (SIR 2.22, 95% CI 1.77–2.73; P < 0.001), breast (SIR 1.31, 95% CI 1.10–1.54; P = 0.003), and hematological (SIR 2.03, 95% CI 1.52–2.62; P < 0.001) cancers. Cancer was associated with older age at SSc onset (odds ratio [OR] 1.22, 95% CI 1.01–1.03; P < 0.001), the presence of primary biliary cholangitis (OR 2.35, 95% CI 1.18–4.68; P = 0.015) and forced vital capacity <70% (OR 1.8, 95% CI 1.24–2.70; P = 0.002). The presence of anticentromere antibodies lowered the risk of cancer (OR 0.66, 95% CI 0.45–0.97; P = 0.036).
Conclusions
Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk. |
| dc.language.iso | eng |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | Autoimmunity Reviews;21(10) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Autoanticossos |
| dc.subject | Càncer - Complicacions |
| dc.subject | Esclerosi sistemàtica progressiva - Complicacions |
| dc.subject.mesh | Scleroderma, Systemic |
| dc.subject.mesh | Neoplasms |
| dc.subject.mesh | Autoantibodies |
| dc.title | Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE) |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.autrev.2022.103167 |
| dc.subject.decs | esclerodermia sistémica |
| dc.subject.decs | neoplasias |
| dc.subject.decs | autoanticuerpos |
| dc.relation.publishversion | https://doi.org/10.1016/j.autrev.2022.103167 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Carbonell C, Marcos M] Department of Internal Medicine, Hospital Universitario de Salamanca, Universidad de Salamanca-IBSAL, Salamanca, Spain. [Guillén-Del-Castillo A, Fonollosa-Pla V, Simeón-Aznar CP] Unitat de Malalties Autoimmunes, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Rubio-Rivas M] Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. [Argibay A] Unit of Systemic Autoimmune Diseases and Thrombosis, Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain. [Marín-Ballvé A] Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, IIS Aragón. Zaragoza, Spain |
| dc.identifier.pmid | 35931315 |
| dc.identifier.wos | 000856598500009 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |